Dental Digital Workflow · SIX: STMN
Straumann Group: a dental ecosystem where 3D printing strengthens implants, prosthetics and chairside workflows rather than standing alone.
Straumann combines intraoral scanning, cloud connectivity, treatment planning, P and PRO series printers, validated resins, washing, curing and restorative or implant workflows. Its additive bottleneck is clinical integration, material validation and channel access—not printer hardware by itself.
As of: 18 July 2026 · Profile: Dental and medical AM workflow · Recommendation: None
Quick research snapshot
AM exposure: Medium
Pure-play score: 1 / 5
Bottleneck score: 4 / 5
Evidence: Qualified
Financial materiality: Emerging
Main risk: Dental demand, workflow adoption and fragmented lab economics.
Research verdict: Straumann combines scanners, software, printers, materials and implant workflows into a credible dental-production ecosystem; additive manufacturing supports platform stickiness but is not a separately disclosed earnings stream.
Investor read
Straumann started 2026 with broad-based organic growth and then raised its profitability outlook in June. Q1 revenue reached CHF 672.5 million, representing 7.1% organic growth, although reported revenue declined 1.2% because of currency headwinds.
Management continues to expect high-single-digit organic revenue growth for 2026 and raised expected core EBIT margin expansion to approximately 140–170 basis points at constant 2025 exchange rates, from the previous 30–60 basis-point range.
3D printing is strategically important because it increases in-house production, shortens treatment workflows and strengthens recurring resin and digital-service attachment. Financial materiality remains unknown: printer revenue, installed base, resin consumption, utilization and AM margins are not separately disclosed.
High-signal metrics
| Metric | Period | Investor interpretation |
|---|---|---|
| CHF 672.5M revenue | Q1 2026 | Down 1.2% reported but up 7.1% organically. |
| 7.8% EMEA organic growth | Q1 2026 | Largest region remained healthy. |
| 7.7% North America organic growth | Q1 2026 | Improved commercial execution and demand. |
| 0.5% APAC organic growth | Q1 2026 | China and regional mix remained a key swing factor. |
| 19.5% Latin America organic growth | Q1 2026 | Strongest regional expansion. |
| High-single-digit organic growth outlook | FY2026 | Maintained in June. |
| 140–170 bps core EBIT margin expansion | FY2026 outlook | Raised materially from 30–60 bps. |
Business and workflow model
| Layer | Capability | Economic role |
|---|---|---|
| Implantology | Premium and challenger implant brands | Core franchise, installed clinical channel and recurring components. |
| Digital capture | Intraoral scanners and case acquisition | Creates patient-specific geometry. |
| Cloud and workflow | AXS and connected treatment processes | Links planning, files, partners and production. |
| 3D printing | P series, PRO series and SprintRay-linked systems | Enables in-house models, guides, dentures and restorations. |
| Post-processing | Wash and cure equipment | Controls final material properties and process repeatability. |
| Consumables | PRO, P pro and partner resin portfolios | Creates recurring revenue and indication-specific attachment. |
| Education and support | Digital Academy, training and service | Reduces workflow errors and accelerates customer adoption. |
Why Straumann controls a dental-AM bottleneck
- Clinical channel: implant, laboratory and dental-practice relationships create distribution leverage.
- Validated workflow: printers, resins, wash and cure equipment are offered as a coordinated system.
- Material breadth: models, guides, dentures, crowns, bridges, gingiva masks and casting applications create recurring demand.
- Digital integration: scanning, cloud and production workflows reduce file-transfer and case-management friction.
- Brand trust: medical-device quality, support and training can matter more than printer specifications.
- Multi-segment economics: printing can reinforce implants, prosthetics, orthodontics and digital services.
- Global manufacturing: regional production and commercial infrastructure support scale and regulatory adaptation.
Financial materiality
Emerging: AM can influence a business line or the strategic thesis, but is not yet dominant.
Addithive scorecard
| Dimension | Assessment | Rationale |
|---|---|---|
| Pure-play | 1 / 5 | AM is a small capability inside a diversified company. |
| Bottleneck ownership | 4 / 5 | Qualified or serial capability with meaningful switching costs, while viable alternatives remain. |
| Evidence maturity | Serial | Repeat production or recurring commercial deployment is demonstrated. |
| Financial materiality | Emerging | AM can influence a business line or the strategic thesis, but is not yet dominant. |
| Substitutability | Medium | Alternatives exist, but replacement requires workflow changes, requalification or integration effort. |
| Evidence confidence | High for cited operational evidence; lower for AM economics | Product, qualification and production claims are source-backed; AM-specific revenue and margin disclosure is often limited. |
Catalysts and thesis breakers
Catalysts
- Printer placements and resin consumption accelerating.
- Chairside permanent-restoration workflows gaining adoption.
- AXS increasing digital case connectivity and recurring services.
- High-single-digit organic growth continuing.
- Core EBIT margin expansion reaching the raised range.
- China local manufacturing improving profitability.
- Dental labs consolidating around validated end-to-end ecosystems.
Thesis breakers
- Open printer-resin ecosystems eroding workflow attachment.
- AM hardware commoditizing faster than consumables scale.
- China VBP or patient demand pressuring growth and margins.
- Currency headwinds overwhelming organic performance.
- Digital products failing to improve customer retention.
- Regulatory or clinical issues limiting printed indications.
- AM remaining too small to affect group economics.
Valuation context
Straumann should be valued on organic implant growth, market-share gains, digital workflow adoption, core EBIT margins, China economics, currency and the quality of recurring consumables and services. The company can command a quality premium, but that also raises the execution hurdle.
Dental AM supports ecosystem depth rather than a separate valuation. A distinct additive premium would require disclosed placements, resin attach, utilization and evidence that printing increases customer lifetime value or treatment volumes.
What to monitor
- Half-year 2026 results on 19 August.
- Organic versus reported revenue growth.
- Core EBIT margin expansion against raised guidance.
- Printer placements, resin sales and digital-equipment growth.
- AXS adoption and connected cases.
- China pricing, patient flow and local-production economics.
- New validated restorative and orthodontic printing indications.
Evidence gaps
- AM revenue, installed base, utilization, resin attach and margins are not disclosed.
- Digital Solutions growth is not separated into scanners, printers, software and consumables.
- Printer economics by practice versus laboratory are unavailable.
- Financial impact of SprintRay-linked products is not quantified.
- Current consensus, ownership and AM-specific capital employed were not sourced.
Source ledger
- Straumann Q1 2026 results — revenue, organic growth and regional performance.
- June 2026 profitability guidance update — raised core EBIT margin outlook.
- Straumann dental printer portfolio — P, PRO and chairside systems plus wash and cure equipment.
- Straumann 3D printing resins — material portfolio.
- P pro resin workflow — medical-device compliance and indications.
- Straumann digital solutions — integrated scanner, printer and resin positioning.
- Straumann investor relations — reporting and event schedule.
Research conclusion
Straumann is a high-quality dental workflow owner with meaningful additive capability, not a dental-printer pure-play.
3D printing strengthens the company’s ability to connect scanning, planning, implants, prosthetics, restorations and recurring materials. The investment outcome remains driven by organic dental growth, margin execution, China and currency. AM becomes a distinct earnings driver only when printer placements and resin consumption become visible in disclosure.
Research use only. This page is not investment advice.
Return to the Public Additive Manufacturing Companies Directory →